Optimization of magnetic nanoparticles for engineering erythrocytes as theranostic agents
Standard
Optimization of magnetic nanoparticles for engineering erythrocytes as theranostic agents. / Slavu, Laura Maria; Antonelli, Antonella; Scarpa, Emanuele Salvatore; Abdalla, Pasant; Wilhelm, Claire; Silvestri, Niccolò; Pellegrino, Teresa; Scheffler, Konrad; Magnani, Mauro; Rinaldi, Rosaria; Di Corato, Riccardo.
in: BIOMATER SCI-UK, Jahrgang 11, Nr. 9, 02.05.2023, S. 3252-3268.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Optimization of magnetic nanoparticles for engineering erythrocytes as theranostic agents
AU - Slavu, Laura Maria
AU - Antonelli, Antonella
AU - Scarpa, Emanuele Salvatore
AU - Abdalla, Pasant
AU - Wilhelm, Claire
AU - Silvestri, Niccolò
AU - Pellegrino, Teresa
AU - Scheffler, Konrad
AU - Magnani, Mauro
AU - Rinaldi, Rosaria
AU - Di Corato, Riccardo
PY - 2023/5/2
Y1 - 2023/5/2
N2 - The application of superparamagnetic iron oxide nanoparticles (SPIONs) in drug delivery, magnetic resonance imaging, cell tracking, and hyperthermia has been long exploited regarding their inducible magnetic properties. Nevertheless, SPIONs remain rapidly cleared from the circulation by the reticuloendothelial system (RES) or mononuclear phagocyte system, with uptake dependent on several factors such as the hydrodynamic diameter, electrical charge and surface coating. This rapid clearance of SPION-based theranostic agents from circulation is one of the main challenges hampering the medical applications that differ from RES targeting. This work proposes a strategy to render biocompatible SPIONs through their encapsulation in the red blood cells (RBCs). In this work, the research has been focused on the multi-step optimization of chemical synthesis of magnetic nanoparticles (MNPs), precisely iron oxide nanoparticles (IONPs) and zinc manganese-ferrite nanoparticles (Zn/Mn FNPs), for encapsulation in human and murine RBCs. The encapsulation through the transient opening of RBC membrane pores requires extensive efforts to deliver high-quality nanoparticles in terms of chemical properties, morphology, stability and biocompatibility. After reaching this goal, in vitro experiments were performed with selected nanomaterials to investigate the potential of engineered MNP-RBC constructs in theranostic approaches.
AB - The application of superparamagnetic iron oxide nanoparticles (SPIONs) in drug delivery, magnetic resonance imaging, cell tracking, and hyperthermia has been long exploited regarding their inducible magnetic properties. Nevertheless, SPIONs remain rapidly cleared from the circulation by the reticuloendothelial system (RES) or mononuclear phagocyte system, with uptake dependent on several factors such as the hydrodynamic diameter, electrical charge and surface coating. This rapid clearance of SPION-based theranostic agents from circulation is one of the main challenges hampering the medical applications that differ from RES targeting. This work proposes a strategy to render biocompatible SPIONs through their encapsulation in the red blood cells (RBCs). In this work, the research has been focused on the multi-step optimization of chemical synthesis of magnetic nanoparticles (MNPs), precisely iron oxide nanoparticles (IONPs) and zinc manganese-ferrite nanoparticles (Zn/Mn FNPs), for encapsulation in human and murine RBCs. The encapsulation through the transient opening of RBC membrane pores requires extensive efforts to deliver high-quality nanoparticles in terms of chemical properties, morphology, stability and biocompatibility. After reaching this goal, in vitro experiments were performed with selected nanomaterials to investigate the potential of engineered MNP-RBC constructs in theranostic approaches.
KW - Mice
KW - Animals
KW - Humans
KW - Magnetite Nanoparticles/chemistry
KW - Precision Medicine
KW - Magnetic Resonance Imaging/methods
KW - Drug Delivery Systems
KW - Erythrocytes/metabolism
KW - Theranostic Nanomedicine/methods
U2 - 10.1039/d3bm00264k
DO - 10.1039/d3bm00264k
M3 - SCORING: Journal article
C2 - 36939172
VL - 11
SP - 3252
EP - 3268
JO - BIOMATER SCI-UK
JF - BIOMATER SCI-UK
SN - 2047-4830
IS - 9
ER -